RNA Pol II Inhibition and Active Apoptotic Signaling

2026-08-20

Harper et al. show that RNA Pol II inhibition triggers an active apoptotic response through loss of hypophosphorylated RNA Pol IIA, rather than through passive depletion of transcripts and proteins. Their genetic and pharmacological analyses define the Pol II degradation-dependent apoptotic response, providing a framework for interpreting transcription-targeting therapies and apoptosis assay results.

Kidney-Targeted mRNA Nanoparticles and Excipients

2026-08-19

This 2024 Pace University thesis investigates how excipients can overcome an apparent mRNA loading ceiling in polymeric mesoscale nanoparticles intended for kidney delivery. By comparing charge-modifying and stabilizing excipients with an original formulation, the study connects encapsulation efficiency with particle size, cytotoxicity, pharmacokinetics, cellular uptake, and reporter protein expression.

Methylprednisolone: From GR Signal to Bone Readouts

2026-08-19

Methylprednisolone is a synthetic glucocorticoid receptor agonist that connects cytokine suppression with measurable bone injury phenotypes. This article interprets the compound as a mechanistic research tool, using glucocorticoid-induced osteonecrosis data to guide assay selection, controls, and translational reasoning.

ABT-199 (Venetoclax): Selective Bcl-2 Inhibitor

2026-08-18

ABT-199, also called Venetoclax or GDC-0199, is a potent and selective BCL-2 inhibitor for experimental apoptosis research. Its supplier-reported sub-nanomolar affinity, strong separation from BCL-XL and BCL-w, and lack of MCL-1 activity support studies of the mitochondrial apoptosis pathway in hematologic malignancy models.

Biomimetic Chromatography Models Lung Drug Permeability

2026-08-18

This study compares immobilised artificial membrane liquid chromatography and open-tubular capillary electrochromatography, each coupled with mass spectrometry, as biomimetic tools for modelling pulmonary drug permeability. Its findings show that IAM-LC more closely reflects conventional partitioning and apparent permeability, while OT-CEC provides complementary information about phospholipid composition and drug–membrane interactions.

Triacetin Digestion and Hepatic Metabolic Signaling

2026-08-17

The reference study clarifies how triacetin, a short-chain triacylglycerol, is digested and absorbed in rats, showing complete upper-gastrointestinal degradation into acetate and glycerol. Its key implication is that triacetin-derived metabolites may influence hepatic AMPK signaling and lipid metabolism regulation in addition to serving as metabolic substrates.

ABT-199 (Venetoclax) Assay Workflows

2026-08-17

Build more informative apoptosis assays with ABT-199 (Venetoclax), a highly selective BCL-2 probe for separating BCL-2 dependence from broader BH3-protein effects. This workflow combines concentration-response profiling, time-resolved cell-death measurements, and senescence-aware interpretation for hematologic and exploratory solid-tumor models.

Ionomycin Free Acid in FAK Signaling Workflows

2026-08-16

Ionomycin free acid offers a rapid, controllable way to perturb intracellular calcium while studying FAISL–FAK regulation, adhesion, and proteolysis in triple-negative breast cancer models. This guide combines calcium ion transport workflows with practical assay design, reagent handling, and troubleshooting, while distinguishing established findings from proposed experimental extensions.

Nicotinamide Riboside Chloride in RGC Models

2026-08-15

Use Nicotinamide Riboside Chloride (NIAGEN) as a defined NAD+ perturbation tool alongside high-yield iPSC-to-retinal ganglion cell differentiation. This workflow separates effects on cell identity from effects on energy metabolism, enabling more reproducible glaucoma and neurodegenerative disease experiments.

Dacomitinib (PF-00299804) Research Workflows

2026-08-14

Dacomitinib (PF-00299804) gives researchers a durable way to interrogate EGFR, HER2, and HER4 signaling in resistant cancer models. This workflow connects pan-HER pathway measurements with carefully controlled apoptosis, cell-cycle, mitochondrial, and ferroptosis-oriented assays without overstating what the current evidence proves.

Ridaforolimus: Applied mTOR Research Workflows

2026-08-14

Ridaforolimus (Deforolimus, MK-8669) connects nanomolar mTOR pathway control with practical cancer-cell, VEGF, and senescence-model workflows. This guide shows how to pair phospho-signaling measurements with viability, apoptosis, and angiogenesis assays while avoiding common dosing and interpretation errors.

(R,S)-Anatabine: From Aβ Biology to Translation

2026-08-13

A mechanistic and strategic perspective on using (R,S)-Anatabine to connect amyloidogenic processing, neuroinflammation, assay design, and translational decision-making in Alzheimer’s research.

ABT-199 (Venetoclax): Selective BCL-2 Research

2026-08-13

ABT-199, also known as Venetoclax and GDC-0199, is a potent, selective BCL-2 inhibitor for apoptosis and hematologic malignancy research. Its reported biochemical selectivity, B-cell sensitivity, and mitochondrial apoptosis activity support focused assay design rather than assumptions of universal cytotoxicity.

TaASN-B2 Deletion and Wheat Grain Asparagine

2026-08-12

ABT-199: Precision Control of Mitochondrial Apoptosis

2026-08-12

ABT-199, also known as GDC-0199 and Venetoclax, offers a highly selective way to interrogate BCL-2 dependence in hematologic malignancies. This thought-leadership analysis connects its molecular selectivity to apoptosis assay design, interprets new evidence on BCL-xL and MCL-1 co-targeting, and outlines a disciplined path from mechanistic observation to translational decision-making.